123I-Mibg Injection
Clinical Summary
Quick overview from the medicine insert
Indication
Used for diagnostic imaging in patients with neuroblastoma and other neuroendocrine tumors.
Dosage (summary)
Administered as a single intravenous injection of 370 MBq per 2 ml.
Onset of Action / Duration
Imaging results can typically be obtained within 24 hours post-injection.
Special Populations
- Elderly patients
- Patients with renal impairment
- Pediatric patients
Pregnancy & Breastfeeding
Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Caution is advised during lactation.
Key Drug Interactions
- May interact with other radiopharmaceuticals.
- Potential interactions with iodine-containing medications.
Contraindications
- Hypersensitivity to iodine or any component of the formulation.
- Severe renal impairment.
Common side effects
- Nausea
- Vomiting
- Allergic reactions
- Transient changes in thyroid function
Counselling Points
- Inform patients about the purpose of the injection and the imaging process.
- Advise patients to stay hydrated before and after the procedure.
- Discuss potential side effects and the importance of reporting any unusual symptoms.
Serious warnings
- Caution in patients with a history of thyroid disease.
- Monitor renal function in patients with pre-existing renal conditions.
The 123I-Mibg Injection professional information leaflet below is the property of Ithemba Labs and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.